Merck KGaA Bolsters Life Sciences Portfolio with $11.3B Bio-Techne Acquisition
Acquisition of a medical tools maker will be the German group’s biggest in over a decade.
/ 1649 items
#XY↓
Passage Bio to Merge with Remix Therapeutics in All-Stock Deal, Raises $100 Million
The combined company will operate as Remix Therapeutics and raised $100M to advance its RNA-targeted pipeline into 2028.
Raymond James Highlights Viking’s New Amylin-Based Weight Loss Drug VK3019 Entering Clinic
Viking Therapeutics advances its obesity portfolio with the start of a Phase 1 trial for VK3019, a novel dual amylin and calcitonin receptor agonist. Analyst sees major potential.
Cantor Fitzgerald Initiates Overweight Coverage on Silence Therapeutics, Calls Stock “Materially Undervalued”
The firm initiated Overweight coverage citing strong divesiran Phase 2 potential and 160%+ upside.
CEO Moshe Mizrahy’s Group Offers to Take InMode Private at $16.20 Per Share
Board forms special committee to evaluate the offer.
Absci Rockets on Positive ABS-201 Data and $100M Financing Backed by Eli Lilly
Eli Lilly participates in Absci’s $100M equity offering to fund ABS-201, a novel prolactin receptor antibody showing strong safety in Phase 1 for pattern hair loss and endometriosis.